Pyramax
Malaria Prevention (e.g., Seasonal Malaria Chemoprevention)
Phase 2/Phase 3Clinical Development
Key Facts
Indication
Malaria Prevention (e.g., Seasonal Malaria Chemoprevention)
Phase
Phase 2/Phase 3
Status
Clinical Development
Company
About Shinpoong Pharm
Shinpoong Pharm is a public South Korean pharmaceutical company with a strategic focus on anti-infectives, especially for malaria and neglected tropical diseases. Its flagship product, Pyramax, is a WHO-prequalified artemisinin-based combination therapy (ACT) for malaria, representing a significant commercial and public health achievement. The company is expanding its pipeline through internal R&D and partnerships, aiming to solidify its position as a key player in global infectious disease therapeutics. Its operations span development, manufacturing, and commercialization, with a strong emphasis on markets in Asia and Africa.
View full company profile